Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness

• Published in: Drugs in R&D Vol. 3; no. 6; pp. 365 - 373
• Main Authors: Simon, Michael W, Fish, Douglas N, Deeter, Robert G
• Format: Journal Article
• Language: English
• Published: New Zealand 2002
• Subjects: Acyclovir - administration & dosage; Acyclovir - adverse effects; Acyclovir - analogs & derivatives; Acyclovir - blood; Acyclovir - pharmacokinetics; Acyclovir - therapeutic use; Administration, Oral; Adolescent; Antiviral Agents - administration & dosage; Antiviral Agents - adverse effects; Antiviral Agents - blood; Antiviral Agents - pharmacokinetics; Antiviral Agents - therapeutic use; Biological Availability; Child; Child, Preschool; Cross-Over Studies; Epstein-Barr virus; Epstein-Barr Virus Infections - drug therapy; Female; Herpesvirus 4, Human - drug effects; Humans; Intestinal Absorption; Male; Suspensions; Tablets; Valine - administration & dosage; Valine - adverse effects; Valine - analogs & derivatives; Valine - blood; Valine - pharmacokinetics; Valine - therapeutic use

Valaciclovir has in vitro activity against Epstein-Barr virus (EBV) and, because of improved absorption with higher achievable serum concentrations, may be more effective than aciclovir in the treatment of EBV. No studies to date have evaluated the efficacy, safety or proper dosing of valaciclovir i...